Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06339320 · ClinicalTrials.gov registry record · NA

Endoscopic Sleeve Gastroplasty (ESG) for the Treatment of Obesity

A NA study of Obesity and Endoscopic Sleeve Gastroplasty, sponsored by The Methodist Hospital Research Institute.

Recruiting
Registry status
NA
Development phase
150
Enrollment target
2
Study locations

NCT06339320: Recruiting NA study of Obesity and Endoscopic Sleeve Gastroplasty, sponsored by The Methodist Hospital Research Institute.

NCT06339320 is a NA study of Obesity and Endoscopic Sleeve Gastroplasty that is actively recruiting participants, run by The Methodist Hospital Research Institute. The registered enrollment target is 150 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06339320, a NA study of Obesity and Endoscopic Sleeve Gastroplasty, is actively recruiting participants, sponsored by The Methodist Hospital Research Institute.

RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to evaluate endoscopic sleeve gastroplasty (ESG) for the treatment of obesity. The ESG procedure is an U.S. Food and Drug Administration (FDA) approved procedure for the treatment of obesity - patients with a body mass index (BMI) 30-50 kg/m2. This procedure is FDA approved; however, Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP)-Accredited centers (such as Houston Methodist Hospital) must receive approval from an Institutional Review Board (IRB) in order to perform primary procedures, such as ESG, that are not endorsed by the American Society for Metabolic and Bariatric Surgery (ASMBS).

Primary Outcome

Per the ASMBS, IRB approval must be for performing the ESG procedure, and not solely for data collection of outcomes from these procedures, with data collected by the MBSAQIP registry. Therefore, the primary outcome is performing the ESG procedure (defined as ability to successful complete the procedure). Procedural success will be defined by ability to successful reduce the size of the stomach using the Apollo OverStitch or APOLLO ESG and ESG SX systems. Technical success further identified by

Interventions

  • PROCEDURE Endoscopic Sleeve Gastroplasty (ESG)
  • DEVICE Apollo OverStitch endoscopic suturing device

Study Locations (2)

Texas

  • Houston Methodist Hospital - Houston
  • Houston Methodist Hospital - Sugarland - Sugar Land

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2024-02-28
Est. Completion 2033-10
Phase NA

What NCT06339320 shows while recruiting

NCT06339320 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (82% lower).

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Endoscopic Sleeve Gastroplasty (ESG) is the first listed.

NCT06339320 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT06339320 about?

NCT06339320 is a clinical study titled "Endoscopic Sleeve Gastroplasty (ESG) for the Treatment of Obesity". The purpose of this study is to evaluate endoscopic sleeve gastroplasty (ESG) for the treatment of obesity. The ESG procedure is an U.S. Food and Drug Administration (FDA) approved procedure for the treatment of obesity - patients with a body mass index (BMI) 30-50 kg/m2. This procedure is FDA appro...

What is the current status of trial NCT06339320?

This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2024-02-28. Estimated completion is 2033-10.

What conditions does trial NCT06339320 study?

This clinical trial studies the following conditions: Obesity, Endoscopic Sleeve Gastroplasty.

What interventions are being tested in trial NCT06339320?

The interventions under investigation include: Endoscopic Sleeve Gastroplasty (ESG) (PROCEDURE), Apollo OverStitch endoscopic suturing device (DEVICE).

Who is sponsoring clinical trial NCT06339320?

This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06339320 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06339320's enrollment target sits among peer trials

150 370th of 1053 higher than 668 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06339320, the US trial registry maintained by the National Library of Medicine. NCT06339320 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.